The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of of BCOP.
BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.
Target Audience: These recertification activities are intended for the Board-Certified Oncology Pharmacist® (BCOP) and those interested in hormone receptor-positive breast cancer, and secondary malignancies in targeted therapies.
BCOP Clinical Session Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast CancerActivity Number: 0217-9999-24-067-H01-P Contact Hour(s): 2.00 Activity Type: Application Based Learning ObjectivesTreatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer
- Apply recent literature surrounding targeted therapy options in hormone receptor-positive (HR+), early-stage breast cancer.
- Identify characteristics of early-stage HR+ breast cancer patients most likely to benefit from targeted adjuvant therapy.
- Analyze literature regarding the integration of oral selective estrogen receptor degraders into current treatment guidelines.
- Recommend appropriate treatment strategies for patients who qualify to receive inhibitors of the PI3K/AKT pathway.
- Evaluate targeted treatment options beyond endocrine therapy for HR+ metastatic breast cancer.
|
BCOP Clinical Session Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted TherapiesActivity Number: 0217-9999-24-068-H01-P Contact Hour(s): 2.00 Activity Type: Application Based Learning ObjectivesSecondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapies
- Assess clinical data evaluating the integration of PARP inhibitors into the treatment of breast, prostate, ovarian, and pancreatic cancers.
- Identify patients who are appropriate for initiation of PARP inhibitor therapy.
- Describe the pathophysiology, incidence, and risk factors of PARP inhibitor-associated secondary myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
- Summarize treatment paradigm changes with the updated classification of MDS and AML
- Design a treatment strategy for patients with MDS or AML with previous PARP inhibitor exposure.
|
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.